American Association for Cancer Research
Browse

Supplementary Figures and Table Legends from Small molecules targeting histone H4 as potential therapeutics for chronic myelogenous leukemia

Download (14.13 kB)
journal contribution
posted on 2023-03-31, 23:03 authored by C. James Chou, Michelle E. Farkas, Sherry M. Tsai, David Alvarez, Peter B. Dervan, Joel M. Gottesfeld
Supplementary Figures and Table Legends from Small molecules targeting histone H4 as potential therapeutics for chronic myelogenous leukemia

History

ARTICLE ABSTRACT

We recently identified a polyamide-chlorambucil conjugate, 1R-Chl, which alkylates and down-regulates transcription of the human histone H4c gene and inhibits the growth of several cancer cell lines in vitro and in a murine SW620 xenograft model, without apparent animal toxicity. In this study, we analyzed the effects of 1R-Chl in the chronic myelogenous leukemia cell line K562 and identified another polyamide conjugate, 6R-Chl, which targets H4 genes and elicits a similar cellular response. Other polyamide conjugates that do not target the H4 gene do not elicit this response. In a murine model, both 1R-Chl and 6R-Chl were found to be highly effective in blocking K562 xenograft growth with high-dose tolerance. Unlike conventional and distamycin-based alkylators, little or no cytotoxicities and animal toxicities were observed in mg/kg dosage ranges. These results suggest that these polyamide alkylators may be a viable treatment alternative for chronic myelogenous leukemia. [Mol Cancer Ther 2008;7(4):769–78]

Usage metrics

    Molecular Cancer Therapeutics

    Categories

    Keywords

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC